Analytical Data
-
基因名
B4GALT6
- Application
-
别名
4-galactosyltransferase 6; 4-galactosyltransferase; 4-GalTase 6; AA536803; AU022389
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UBX8
-
表达区间
1-382aa
-
氨基酸序列
MSVLRRMMRVSNRSLLAFIFFFSLSSSCLYFIYVAPGIANTYLFMVQARGIMLRENVKTIGHMIRLYTNKNSTLNGTDYPEGNNSSDYLVQTTTYLPENFTYSPYLPCPEKLPYMRGFLNVNVSEVSFDEIHQLFSKDLDIEPGGHWRPKDCKPRWKVAVLIPFRNRHEHLPIFFLHLIPMLQKQRLEFAFYVIEQTGTQPFNRAMLFNVGFKEAMKDSVWDCVIFHDVDHLPENDRNYYGCGEMPRHFAAKLDKYMYILPYKEFFGGVSGLTVEQFRKINGFPNAFWGWGGEDDDLWNRVHYAGYNVTRPEGDLGKYKSIPHHHRGEVQFLGRYKLLRYSKERQYIDGLNNLIYRPKILVDRLYTNISVNLMPELAPIEDY
-
分子量
44 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
B4GALT6, or Beta-1,4-galactosyltransferase 6, is an enzyme that plays a critical role in glycosylation, a vital post-translational modification influencing protein function, stability, and interactions. Abnormalities in glycosylation can lead to various diseases, including congenital disorders of glycosylation (CDGs). B4GALT6 is particularly significant due to its involvement in synthesizing specific glycan structures that are important for cell signaling, adhesion, and immune responses. Research has shown that mutations in the B4GALT6 gene are associated with certain CDGs, highlighting the enzyme's role in human health. Understanding the structure and function of B4GALT6 through recombinant protein studies can provide insights into its enzymatic mechanism and facilitate the development of targeted therapies for diseases linked to glycosylation defects. By producing and characterizing the recombinant B4GALT6 protein, researchers aim to elucidate its biological functions, investigate its substrate specificity, and explore potential therapeutic applications, contributing to a deeper understanding of glycosylation pathways and their implications in health and disease.
